Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cytarabine × Tumor-Agnostic × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 95 Lymphoid 37 Myeloid 21 Classical hematology 4 CNS 2 Tumor-Agnostic 1 Sarcoma 1 Plasma cell 1

Conditions

Interventions

pembrolizumab 16 Nivolumab 15 Gemcitabine 8 Carboplatin 8 Paclitaxel 6 Ipilimumab 6 Capecitabine 6 Irinotecan 5 atezolizumab 4 Trastuzumab 4 Cyclophosphamide 4 Cisplatin 4 trametinib 3 avelumab 3 Specimen Handling 3 Pemetrexed 3 Everolimus 3 Cetuximab 3 Biopsy 3 urelumab 2 toripalimab 2 tislelizumab 2 spartalizumab 2 ribociclib 2 repotrectinib 2 regorafenib 2 olaparib 2 nabiximols 2 fludarabine phosphate 2 aldesleukin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡